Mission
Our mission is to back teams that aim to maximise the potential of alternative medicine with a focus on providing relief from pain, physical and mental stress whilst improving the quality of life for both patients and their families.
At present, one in four people worldwide suffers from pain disorders, substance abuse, anxiety, depression, and other mental health illnesses. The current standard of care has been compromised with its ineffectiveness and numerous side effects, let alone accessibility. In turn, this has created a growing unmet medical need for alternative treatments and novel compounds.
We are confident that psychedelics and cannabis, backed by clinical studies, are poised to become the “next major medical breakthrough” in treating mental health and pain disorders.
Primarily focused on the European market, we are concentrating on building a portfolio of companies that will lead, legitimise and form the future of cannabis and psychedelics in the medical industry. We invest in healthcare disruptors who provide solutions for our mental and emotional well-being.